Baird analyst Colleen Kusy has maintained an "Outperform" rating on Apellis Pharmaceuticals (APLS, Financial) while raising the price target from $47.00 to $50.00 USD. This adjustment reflects a 6.38% increase in the price target.
The updated price target and maintained rating by Baird suggest continued positive expectations for Apellis Pharmaceuticals (APLS, Financial) in the stock market, as assessed by analyst Colleen Kusy. The price target revision is effective as of July 18, 2025.
Investors following Apellis Pharmaceuticals (APLS, Financial) may find this update significant as it highlights confidence in the company's potential for growth, according to the latest analysis from Baird.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Apellis Pharmaceuticals Inc (APLS, Financial) is $35.53 with a high estimate of $60.00 and a low estimate of $18.00. The average target implies an upside of 77.28% from the current price of $20.04. More detailed estimate data can be found on the Apellis Pharmaceuticals Inc (APLS) Forecast page.
Based on the consensus recommendation from 22 brokerage firms, Apellis Pharmaceuticals Inc's (APLS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apellis Pharmaceuticals Inc (APLS, Financial) in one year is $191.17, suggesting a upside of 853.94% from the current price of $20.04. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apellis Pharmaceuticals Inc (APLS) Summary page.
